Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03805477
PHASE2

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation

Sponsor: University Hospital, Basel, Switzerland

View on ClinicalTrials.gov

Summary

This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation. All study patients with BOS will be treated with the study drug Nintedanib (300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months treatment period.

Official title: Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2019-03-20

Completion Date

2026-12

Last Updated

2025-12-15

Healthy Volunteers

No

Interventions

DRUG

Nintedanib

Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily

Locations (3)

King Faisal Specialist Hospital & Research Centre

Riyadh, Saudi Arabia

Clinic of Hematology, University Hospital Basel

Basel, Switzerland

Clinic of Respiratory Medicine, University Hospital Basel

Basel, Switzerland